Similar articles

• Bacterial polysaccharide immune globulin for prophylaxis of acute otitis media in high-risk children.

  Shurin PA, Rehmus JM, Johnson CE, Marchant CD, Carlin SA, Super DM, Van Hare GF, Jones PK, Ambrosino DM, Siber GR. Shurin PA, et al. J Pediatr. 1993 Nov;123(5):801-10. doi: 10.1016/s0022-3476(05)80865-0. J Pediatr. 1993. PMID: 8229496 Clinical Trial.
• Vaccination and otitis media.

  Karma P. Karma P. ORL J Otorhinolaryngol Relat Spec. 2002 Mar-Apr;64(2):80-5. doi: 10.1159/000057785. ORL J Otorhinolaryngol Relat Spec. 2002. PMID: 12021498 Clinical Trial.
• Otitis media: prospects for prevention.

  Haggard M. Haggard M. Vaccine. 2008 Dec 23;26 Suppl 7:G20-4. doi: 10.1016/j.vaccine.2008.11.009. Vaccine. 2008. PMID: 19094934 Review.
• Mathematical model comparisons of potential non-typeable Haemophilus influenzae vaccine effects.

  Lin X, Koopman JS, Chick SE. Lin X, et al. J Theor Biol. 2007 Mar 7;245(1):66-76. doi: 10.1016/j.jtbi.2006.09.034. Epub 2006 Oct 6. J Theor Biol. 2007. PMID: 17098258 Free PMC article.
• Impact of protein D-containing pneumococcal conjugate vaccines on non-typeable Haemophilus influenzae acute otitis media and carriage.

  Clarke C, Bakaletz LO, Ruiz-Guiñazú J, Borys D, Mrkvan T. Clarke C, et al. Expert Rev Vaccines. 2017 Jul;16(7):1-14. doi: 10.1080/14760584.2017.1333905. Epub 2017 Jun 7. Expert Rev Vaccines. 2017. PMID: 28571504 Review.